期刊文献+

三阴性乳腺癌的研究进展 被引量:27

Progress in the study of triple negative breast cancer
下载PDF
导出
摘要 三阴性乳腺癌(triple negative breast cancer,TNBC)是指雌激素受体(estrogen receptor,ER)、孕激素受体(proges-terone receptor,PR)与人类表皮生长因子受体2(human epidermal growth factor receptor-type2,Her-2)均为阴性的一类乳腺癌,其具有侵袭性生物学行为及临床病理特征的一个乳腺癌亚型,与基底细胞样乳腺癌和乳腺癌易感癌基因1(breast cancer suscep-tibitity genel,BRCAI)相关性乳腺癌有一定相关性。此类型乳腺癌对常规标准治疗效果欠佳,易发生远处转移,预后较其他类型乳腺癌差。对TNBC的深入研究,将有助于人们采取有效的治疗方法来提高其疗效。 Triple-negative breast cancer (TNBC) is a subgroup of breast cancers defined by a lack of the expressions of estrogen, progesterone and HER2 receptors, with more aggressive biological and clinicopathological characteristics and a close relationship with basal-like and breast cancer susceptibility gene-1 ( BRCA1 ) -related breast cancers. TNBC is insensitive to most available hormonal or standard therapeutic agents, associated with increased risk for distant metastases and with poorer prognosis than other types of breast cancer. A deeper insight into the biology of TNBC may lead to improved therapies and better clinical outcomes of the disease.
出处 《医学研究生学报》 CAS 2010年第1期105-109,共5页 Journal of Medical Postgraduates
基金 南京军区南京总医院科研基金(2005045)
关键词 三阴性乳腺癌 基底细胞样乳腺癌 乳腺癌易感癌基因 预后 治疗 Triple negative breast cancer Basal-like breast cancer Breast cancer susceptibility gene Prognosis Therapy
  • 相关文献

参考文献3

二级参考文献65

  • 1王少华,于泽平,李宁,杨小冬,张新华,孙桂勤,黎介寿.原发性乳腺浸润性导管癌组织中生长抑素受体表达及其意义[J].医学研究生学报,2005,18(9):805-807. 被引量:8
  • 2王少华,于泽平,李宁,黎介寿.生长抑素与乳腺癌的研究进展[J].医学研究生学报,2006,19(12):1125-1128. 被引量:4
  • 3赵卫红,徐兵河,张频,李青,赵龙妹,孙燕.乳腺癌合并脉管瘤栓的临床病理特点及预后因素分析[J].中华肿瘤杂志,2007,29(2):137-140. 被引量:14
  • 4顾军,于泽平.原发性双侧乳腺癌的临床分析[J].医学研究生学报,2007,20(6):631-633. 被引量:12
  • 5Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA, 2006, 295:2492-2502.
  • 6Carlson RW, Moench SJ, Hammond ME, et al. HER2 testing in breast cancer: NCCN Task Force report and recoannendations. J Natl Compr Canc Netw, 2006, 4 Suppl 3 :S1-22.
  • 7Cleator S, Heller W, Coombes RC. Triple-negative breast cancer: therapeutic options. Lancet Oncol, 2007, 8:235-244.
  • 8Rakha EA, El-Sayed ME, Green AR, et al. Prognostic markers in triple-negative breast cancer. Cancer, 2007, 109:25-32.
  • 9Perez EA, Roche PC, Jenkins RB, et al. HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clin Proc, 2002, 77:148-154.
  • 10Kandel MJ, Stadler Z, Masciari S, et al. Prevalence of BRCA1 mutations in triple negative breast cancer (BC). Proc Am Soc Clin Oncol, 2006, 24 :abstr 508.

共引文献97

同被引文献351

引证文献27

二级引证文献169

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部